ClinicalTrials.gg
Active, not recruitingNCT05976243Updated Oct 15, 2026

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

A Phase 3 interventional study of Remibrutinib and Placebo in Chronic Inducible Urticaria, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 130 sites in 28 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Updated Oct 15, 20264 sites added4 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
362
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE).

The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability of remibrutinib (LOU064) vs. placebo in adults suffering from CINDU inadequately controlled by H1-antihistamines (H1-AHs).

The purpose of the OLE period is to collect long-term efficacy, safety, and tolerability data on remibrutinib in participants after having completed the Core period

Read the detailed description

This study consists of a core and extension periods.

The Core period (6 arms) has a total duration of up to 60 weeks including a double-blind placebo-controlled treatment period until Week 24 followed by open-label treatment with remibrutinib up to Week 52. The primary endpoint for all CINDU subtypes is assessed at Week 12.

The Core period consists of:

  • Screening period (up to 4 weeks): During the screening period, participants who have provided informed consent will be assessed for study eligibility.
  • Double-blind, placebo-controlled treatment period (24 weeks): 24 weeks of double-blind treatment with remibrutinib or placebo.
  • Open-label treatment period (28 weeks): 28 weeks of open-label treatment with remibrutinib.
  • Follow-up period: 4 weeks of treatment free follow-up. The open-label extension period consists of observation and treatment period. At the end of the core period of the study, if participants continue to experience symptoms, they will transition to the treatment period in OLE. If they do not experience symtpoms they will transition to the observation period in the OLE.

The duration of the Open-label Extension period will be approximately 3 years where participants can switch from observation to treatment depending on if they start developing symptoms. Only those participants participating in the Open-label Extension Treatment period will receive remibrutinib. The participants in the Open-label Extension Observation period will not receive remibrutinib

02

Conditions studied

  • Chronic Inducible Urticaria

Keywords

  • CINDU
  • Chronic inducible urticaria
  • BTK
  • remibrutinib
  • symptomatic dermographsim
  • cold urticaria
  • cholinergic urticaria
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for core period:

  1. Male and female participants ≥18 years of age at the time of signing of the ICFs
  2. Confirmed CINDU diagnosis (as per guidelines) for symptomatic dermographism, cold urticaria or cholinergic urticaria for ≥ 4 months (defined as onset of CINDU with supporting documentation (e.g medical record, clinical history, photographs)) and inadequate control with H1-AH at local label approved doses at the time of randomization
  3. The following response to the provocation test for each subtype is required at the randomization visit :

    • Symptomatic Dermographism: A Total Fric Score of ≥3 using the FricTest® 4.0 and a numerical rating scale score of ≥5 for itch after the provocation test.
    • Cold Urticaria: A Critical Threshold Temperature of ≥15°C using the TempTest® 4.0 and a numerical rating scale score of ≥5 for itch after the provocation test.
    • Cholinergic Urticaria: A physician global assessment of severity of hives ≥ 2 using the Pulse-controlled ergometry test and a numerical rating scale score of ≥5 for itch after the provocation test.
  4. Cold Urticaria: Positive ice-cube test resulting in hives at the provocation site for participants at Screening.
  5. Cholinergic urticaria: Participants must show sweating in performing the pulse-controlled ergometry test on day of randomization. Participants with anhidrosis must not be included.

Inclusion criteria for the OLE:

  1. Participants who have completed the Core period up to Week 52 and are willing to enter the OLE period

    Exclusion Criteria for core period:

    • 1. Previous use of remibrutinib or other BTK inhibitors.
  2. Participants who have concomitant CSU at screening. Participants with resolved CSU at the time of screening can be included in the study.
  3. Participants who have a familial form (e.g familial cold autoinflammatory syndrome, familial cold urticaria) of the target CINDU that is being considered for the participant's inclusion in this study.
  4. Participants having a more defined other form of inducible urticaria than the target CINDU that is being considered for the participant's inclusion in this study.
  5. Diseases, other than chronic inducible urticaria, with urticaria or angioedema symptoms including but not limited to urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema
  6. Any other skin disease associated with chronic itching that might influence, in the investigator's opinion, the study evaluations and results (e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.) or skin diseases associated with only wheals and no itch e.g asymptomatic dermographism

There are no exclusion criteria for OLE

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
362 participants (actual)

Study arms

  • Experimental
    Remibrutinib, symptomatic dermographism group

    Remibrutinib oral twice daily in participants with symptomatic dermographism

    Drug: Remibrutinib

  • Placebo comparator
    Placebo, symptomatic dermographism group

    Placebo oral twice daily, symptomatic dermographism

    Other: Placebo

  • Experimental
    Remibrutinib, cold urticaria group

    Remibrutinib oral twice daily, cold urticaria

    Drug: Remibrutinib

  • Placebo comparator
    Placebo, cold urticaria group

    Placebo oral twice daily, cold urticaria

    Other: Placebo

  • Experimental
    Remibrutinib, cholinergic urticaria group

    Remibrutinib oral twice daily, cholinergic urticaria

    Drug: Remibrutinib

  • Placebo comparator
    Placebo, cholinergic urticaria

    Placebo oral twice daily, cholinergic urticaria

    Other: Placebo

Interventions

  • Remibrutinib treated groups and arms

  • OtherPlacebo

    Placebo treated groups and arms

06

What researchers measure

Primary outcomes

  1. Proportion of participants with complete response in Total Fric Score; symptomatic dermographism

    Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)

    Time frame: Week 12

  2. Proportion of participants with complete response in critical temperature threshold; cold urticaria

    The Temptest is used to induce itch and hives in participants with cold urticaria. Critical temperature threshold (CTT), as measured by the Temptest, determines the highest temperature that induces symptoms.

    Time frame: Week 12

  3. Proportion of participants with itch numerical rating scale =0; cholinergic urticaria

    Itch numerical rating scale, a scale from 0 to 10 Patients are asked to rate itching severity based on the worst level of itching in the past 24 h using an 11-point scale from 0 ("no itch") to 10 ("worst itch imaginable")

    Time frame: Week 12

Secondary outcomes

  1. Change from baseline in Total Fric score; symptomatic dermographism

    Total Fric score, a scale from 0-4 where a positive response with all four pins is TFS=4, while a positive only 1 pin - the largest pin is TFS=1

    Time frame: Week 12

  2. Change from baseline in criticial temperature threshold following Temptest; cold urticaria

    Critical temperature threshold, as measured by the Temptest, determines the highest temperature that induces symptoms

    Time frame: Week 12

  3. Change from baseline in itch numerical rating scale; cholinergic urticaria

    Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").

    Time frame: Week 12

  4. proportion of participants with Physician Global Assessment (PGA) severity of hives =0; cholinergic urticaria

    Physician global assessment of severity of hives. This assessment is scored 0 to 4 with 0=no hives, 1=mild hives, 2=moderate hives, 3=severe hives and 4=very severe hives

    Time frame: Week 12

  5. Proportion of participants with complete response in TFS; symptomatic dermographism

    Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)

    Time frame: Week 24

  6. Proportion of participants with complete response in Critical Temperature threshold; cold urticaria

    Critical Temperature Threshold, as measured by the Temptest, is the highest temperature that induces symptoms

    Time frame: Week 24

  7. Proportion of participants with complete response in itch numerical rating scale; cholinergic urticaria

    Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").

    Time frame: Week 24

  8. Change from baseline in itch numerical rating scale in participants with symptomatic dermographism

    Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").

    Time frame: Week 12

  9. Change from baseline in itch numerical rating scale in participants with cold urticaria

    Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").

    Time frame: Week 12

  10. Proportion of participants with complete response in Total Fric score; symptomatic dermographism

    Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)

    Time frame: Week 2

  11. Proportion of participants with complete response in Critical Temperature Threshold; cold urticaria

    Critical temperature threshold (CTT), as measured by the Temptest, determines the highest temperature that induces symptoms.

    Time frame: Week 2

  12. Proportion of participants with itch NRS=0; cholinergic urticaria

    Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").

    Time frame: Week 2

  13. Change from baseline in TFS in participants with symptomatic dermographism

    Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)

    Time frame: Week 2

  14. Change from baseline in Critical Temperature Threshold in participants with cold urticaria

    Critical temperature threshold (CTT), as measured by the Temptest, determines the highest temperature that induces symptoms.

    Time frame: Week 2

  15. Change from baseline in itch NRS in participants with cholinergic urticaria

    Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").

    Time frame: Week 2

  16. Change from baseline in itch NRS in participants with symptomatic dermographism

    Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)

    Time frame: Week 2

  17. Change from baseline in itch NRS in participants with cold urticaria

    Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").

    Time frame: Week 2

  18. Proportion of participants with cholinergic urticaria with PGA=0

    Physician global assessment of severity of hives is a 4-point scale (0 = no active disease, 1 = mild disease, 2 = moderate disease, 3 = severe disease).

    Time frame: Week 2

  19. Change from baseline in weekly most bothersome symptom NRS score on the USDD

    Urtricara symptom daily diary (USDD). This daily diary records if the participant experiences any symptoms or avoided the triggers

    Time frame: Week 12

  20. Proportion of participants with DLQI=0-1

    The Dermatology Life Quality Index (DLQI) is a 10-item dermatology-specific quality of life (QoL) measure. Subjects rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). A DLQI score of 0 or 1 means that there is no impact of a skin disease on the patient's life.

    Time frame: Week 12

  21. Occurrence of treatment emergent adverse events and serious adverse events during the study

    Treatment emergent adverse events and serious adverse events are those that occur at any time only after treatment has started

    Time frame: Week 52

07

Study locations

130 sites
  • AllerVie Clinical Research-Homewood
    Birmingham, Alabama 35209, United States
  • Acuro Research Inc
    Little Rock, Arkansas 72205, United States
  • Kern Research
    Bakersfield, California 93301, United States
  • Allergy and Asthma Specialists Group
    Huntington Beach, California 92647, United States
  • Antelope Valley Clinical Trials
    Lancaster, California 93534, United States
  • Asthma and Allergy Associates P C
    Colorado Springs, Colorado 80907, United States
  • Florida Ctr Allergy Asthma Research
    Aventura, Florida 33180, United States
  • Sarasota Clinical Research
    Sarasota, Florida 34233, United States
  • Univ of South Florida Asthma Allergy and Immunology CRU
    Tampa, Florida 33613, United States
  • Aeroallergy Research Laboratories
    Savannah, Georgia 31406, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • Endeavor Health
    Glenview, Illinois 60077, United States
  • Asthma and Allergy Center of Chicago S C
    River Forest, Illinois 60305, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • Allergy and Asthma Specialist P S C
    Owensboro, Kentucky 42301, United States
  • John Hopkins University
    Baltimore, Maryland 21204, United States
  • Allergy Asthma and Clinical Research
    Oklahoma City, Oklahoma 73120, United States
  • Allergy and Clinical Immunology Associates
    Pittsburgh, Pennsylvania 15241, United States
  • National Allergy and Asthma Research LLS
    North Charleston, South Carolina 29420, United States
  • PanAmerican Clinical Research
    Brownsville, Texas 78520, United States
  • Western Sky Medical Research
    El Paso, Texas 79924, United States
  • RFSA Dermatology
    San Antonio, Texas 78213, United States
  • STAAMP Research LLC
    San Antonio, Texas 78229, United States
  • Complete Dermatology
    Sugarland, Texas 77479, United States
  • Allergy Associates of Utah
    Sandy City, Utah 84093, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1121ABE, Argentina
  • Novartis Investigative Site
    CABA, Buenos Aires C1414AIF, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000DBS, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000DEJ, Argentina
  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
  • Novartis Investigative Site
    Greenslopes, Queensland 4102, Australia
  • Novartis Investigative Site
    Carlton, Victoria 3053, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
  • Novartis Investigative Site
    Alphaville Barueri, São Paulo 06454-010, Brazil
  • Novartis Investigative Site
    Santo André, São Paulo 09060-870, Brazil
  • Novartis Investigative Site
    Sorocaba, São Paulo 18040-425, Brazil
  • Novartis Investigative Site
    Winnipeg, Manitoba R3J 0S9, Canada
  • Novartis Investigative Site
    Hamilton, Ontario L8L 3C3, Canada
  • Novartis Investigative Site
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Novartis Investigative Site
    Fuzhou, Fujian 350025, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510091, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510630, China
  • Novartis Investigative Site
    Changsha, Hunan 410008, China
  • Novartis Investigative Site
    Wuxi, Jiangsu 214002, China
  • Novartis Investigative Site
    Changchun, Jilin 130021, China
  • Novartis Investigative Site
    Jinan, Shandong 250022, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610072, China
  • Novartis Investigative Site
    Ürümqi, Xinjiang 830001, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310001, China
  • Novartis Investigative Site
    Yiwu, Zhejiang 322000, China
  • Novartis Investigative Site
    Beijing, 100050, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Jinan, 250012, China
  • Novartis Investigative Site
    Shanghai, 200040, China
  • Novartis Investigative Site
    Tianjin, 300052, China
  • Novartis Investigative Site
    Barranquilla, Atlántico 080002, Colombia
  • Novartis Investigative Site
    Barranquilla, Atlántico 080020, Colombia
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Nantes, 44093, France
  • Novartis Investigative Site
    Paris, 75970, France
  • Novartis Investigative Site
    Pierre-Bénite, 69495, France
  • Novartis Investigative Site
    Rouen, 76031, France
  • Novartis Investigative Site
    Toulouse, 31400, France
  • Novartis Investigative Site
    Göttingen, Lower Saxony 37075, Germany
  • Novartis Investigative Site
    Stade, Lower Saxony 21682, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Münster, 48149, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Hong Kong, 999077, Hong Kong
  • Novartis Investigative Site
    Debrecen, Hajdu Bihar Megye 4032, Hungary
  • Novartis Investigative Site
    Debrecen, Hajdú-Bihar 4031, Hungary
  • Novartis Investigative Site
    Szolnok, Jász-Nagykun-Szolnok 5000, Hungary
  • Novartis Investigative Site
    Bangalore, Karnataka 560004, India
  • Novartis Investigative Site
    Mysore, Karnataka 570001, India
  • Novartis Investigative Site
    Haifa, 3104802, Israel
  • Novartis Investigative Site
    Jerusalem, 9112001, Israel
  • Novartis Investigative Site
    Ramat Gan, 5265601, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Ancona, AN 60020, Italy
  • Novartis Investigative Site
    Milan, MI 20122, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Kitakyushu, Fukuoka 8078556, Japan
  • Novartis Investigative Site
    Sapporo, Hokkaido 0608543, Japan
  • Novartis Investigative Site
    Kamimashi-gun, Kumamoto 8613106, Japan
  • Novartis Investigative Site
    Habikino, Osaka 5838588, Japan
  • Novartis Investigative Site
    Takatsuki, Osaka 5698686, Japan
  • Novartis Investigative Site
    Ōtsu, Shiga 520-2192, Japan
  • Novartis Investigative Site
    Izumo, Shimane 6938501, Japan
  • Novartis Investigative Site
    Bunkyo-ku, Tokyo 1138519, Japan
  • Novartis Investigative Site
    Itabashi-ku, Tokyo 1738610, Japan
  • Novartis Investigative Site
    Shinjuku Ku, Tokyo 1600023, Japan
  • Novartis Investigative Site
    Tachikawa, Tokyo 1900023, Japan
  • Novartis Investigative Site
    Hiroshima, 7308518, Japan
  • Novartis Investigative Site
    Muar town, Johor 84000, Malaysia
  • Novartis Investigative Site
    Ipoh, Perak 30450, Malaysia
  • Novartis Investigative Site
    George Town, Pulau Pinang 10450, Malaysia

Showing the first 100 of 130 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in May 2026, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 4, 2023
StartActual
Dec 7, 2023
Primary completionActual
May 11, 2026
CompletionEst.
Jun 15, 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (1 United States, 1 Argentina, 1 Australia, 1 Japan)
  • AllerVie Clinical Research-Homewood · Birmingham, United States
  • Novartis Investigative Site · Rosario, Argentina
  • Novartis Investigative Site · Greenslopes, Australia
  • Novartis Investigative Site · Ōtsu, Japan
Show 4 removed
  • Allervie Clinical Research · Birmingham, United States
  • Novartis Investigative Site · Woolloongabba, Australia
  • Novartis Investigative Site · Ohtsu, Japan
  • Novartis Investigative Site · Santiago, Spain
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    4 sites added, 4 sites removed
    Show 4 added (1 United States, 1 Argentina, 1 Australia, 1 Japan)
    • AllerVie Clinical Research-Homewood · Birmingham, United States
    • Novartis Investigative Site · Rosario, Argentina
    • Novartis Investigative Site · Greenslopes, Australia
    • Novartis Investigative Site · Ōtsu, Japan
    Show 4 removed
    • Allervie Clinical Research · Birmingham, United States
    • Novartis Investigative Site · Woolloongabba, Australia
    • Novartis Investigative Site · Ohtsu, Japan
    • Novartis Investigative Site · Santiago, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05976243
Responsible party
Sponsor
First posted
Aug 4, 2023
Start date
Dec 7, 2023
Primary completion
May 11, 2026
Completion
Jun 15, 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion